351324-52-2

Basic information

• Product Name: 1-[4-Nitro-2-(trifluoroMethyl)phenyl]iMidazole
• Synonyms: 1-[4-Nitro-2-(trifluoroMethyl)phenyl]iMidazole
• CAS NO: 351324-52-2
• Molecular Formula: C₁₀H₆F₃N₃O₂
• Molecular Weight: 257.1687496
• Mol File: 351324-52-2.mol

Chemical Properties

• Boiling Point: 359.6±42.0 °C(Predicted)
• Appearance: /
• Density: 1.49±0.1 g/cm3(Predicted)
• PKA: 4.25±0.10(Predicted)
• CAS DataBase Reference: 1-[4-Nitro-2-(trifluoroMethyl)phenyl]iMidazole(CAS DataBase Reference)
• NIST Chemistry Reference: 1-[4-Nitro-2-(trifluoroMethyl)phenyl]iMidazole(351324-52-2)
• EPA Substance Registry System: 1-[4-Nitro-2-(trifluoroMethyl)phenyl]iMidazole(351324-52-2)

Safety Data

• Hazardous Substances Data: 351324-52-2(Hazardous Substances Data)

Usage

Chemical structure

A derivative of imidazole with a nitro and trifluoromethyl substituent on the phenyl ring.

Usage

Commonly used in pharmaceutical and agricultural industries.

Potential applications

a. Anti-inflammatory and analgesic agent.
b. Antifungal and antibacterial properties.
c. Building block in the synthesis of other pharmaceutical compounds.

Hazardous nature

Considered hazardous and may cause irritation to the skin, eyes, and respiratory system.

Handling precautions

Should be handled with caution to avoid exposure and potential health risks.

Upstream product

• 288-32-4 1H-imidazole 
• 400-74-8 2-Fluoro-5-nitrobenzotrifluoride 

Downstream Products

• 759419-73-3 N-(4-Imidazol-1-yl-3-trifluoromethyl-phenyl)-guanidine 
• 351324-53-3 4-(1H-imidazol-1-yl)-3-(trifluoromethyl)benzamine 

Relevant articles and documents

Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use

Amide compounds that modulate and/or inhibit the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction in order to modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer as well as other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.

Preparation of Substituted N-Phenyl-4-aryl-2-pyrimidinamines as Mediator Release Inhibitors

The role of immunologically released mediators, such as histamine, leukotrienes, and platelet-activating factor, is well-established for asthma and other allergic disorders.Developing therapeutic agents which would block mediator release from mast cells and other relevant cell types would provide a rational approach to asthma therapy.Using human basophil as a screen, a series of 4-aryl-2-(phenylamino)pyrimidines was found which inhibited mediator release.These compounds were prepared by condensing acetyl heterocycles with dimethylformamide dimethyl acetal to form enaminones which are cyclized with aryl guanidines to give pyrimidines.After examining a large number of analogs, N--4-(2-pyridinyl)-2-pyrimidinamine (1-27) was chosen for toxicological evaluation.